MetaCap

BioLineRx (BLRX) vs Pulmatrix (PULM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioLineRx is the larger company by market cap ($4.8 million vs $4.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLRX-56.29%PULM-14.77%
+8%-25%-59%
Oct 7, 20261 yearNov 20, 2026
BLRX-56.50%PULM-13.01%
+4%-28%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLRX versus PULM key metrics
MetricBLRXPULM
Share price$0.9639$1.27
Market cap$4.80M$4.64M
1-day change-8.20%-10.56%
YTD return-65.20%—
1-year return-70.34%—
5-year return-99.07%—
EPS (TTM)$0.00$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.18M—
Revenue growth (YoY)-95.92%—
Net income (latest FY)$-2.03M$-5.16M
Gross margin80.51%—
Operating margin-871.78%—
Net margin-171.69%—
52-week high$3.95$4.94
52-week low$0.78$1.06
Distance from 52-week high-75.60%-74.29%
Analyst consensusnone—
Avg. price target upside+2182.39%—
Average volume23.43K35.45K
Shares outstanding4.98M3.65M
Employees202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioLineRx

BLRX stock →

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Pulmatrix

PULM stock →

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

BLRX vs PULM FAQ

Which is bigger, BioLineRx or Pulmatrix?

BioLineRx (BLRX) is larger, with a market capitalization of $4.80M compared with $4.64M for Pulmatrix (PULM).

Are BioLineRx and Pulmatrix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons